ABEO Stock Overview
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Abeona Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.36 |
| 52 Week High | US$9.01 |
| 52 Week Low | US$2.83 |
| Beta | 1.48 |
| 1 Month Change | -3.29% |
| 3 Month Change | 54.62% |
| 1 Year Change | 125.77% |
| 3 Year Change | -82.48% |
| 5 Year Change | -96.18% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate
Jan 04
Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation
Aug 16Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?
Mar 31Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value
Oct 19Abeona Therapeutics stock continues recent strong run, shares rise ~10%
Oct 04Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M
Aug 11Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement
Jul 20Abeona crashes 21% as reverse stock split takes effect
Jul 05Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely
Mar 02Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money
Aug 17Abeona Therapeutics shares rise after letter to stockholders
May 26Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt
Apr 28Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)
Feb 21How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 19What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?
Dec 15
Shareholder Returns
| ABEO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.2% | -2.5% | -3.2% |
| 1Y | 125.8% | -3.7% | 19.3% |
Return vs Industry: ABEO exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: ABEO exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| ABEO volatility | |
|---|---|
| ABEO Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABEO's share price has been volatile over the past 3 months.
Volatility Over Time: ABEO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 84 | Vish Seshadri | www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
Abeona Therapeutics Inc. Fundamentals Summary
| ABEO fundamental statistics | |
|---|---|
| Market cap | US$201.33m |
| Earnings (TTM) | -US$54.19m |
| Revenue (TTM) | US$3.50m |
57.5x
P/S Ratio-3.7x
P/E RatioIs ABEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABEO income statement (TTM) | |
|---|---|
| Revenue | US$3.50m |
| Cost of Revenue | US$2.69m |
| Gross Profit | US$810.00k |
| Other Expenses | US$55.00m |
| Earnings | -US$54.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 23.14% |
| Net Profit Margin | -1,548.23% |
| Debt/Equity Ratio | 0% |
How did ABEO perform over the long term?
See historical performance and comparison